For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

randomized to receive tirzepatide (5, 10, or 15 mg) who were treatment adherent (at least 75% doses received), all of whom initially had either obesity (body mass index, or BMI, of greater than ...

Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat ...

Four percent initiated tirzepatide, and these patients were slightly younger (58 vs 66 years). Patients with incident use, however, often had a higher body mass index and lower hemoglobin A 1c and ...

Compared with semaglutide and insulin, tirzepatide was associated with improved glycemic control and weight loss outcomes among patients with type 2 diabetes. Tirzepatide is associated with longer ...

Investigators from Mass General Brigham looked at claims data ... climb in the use of newly approved medications, especially tirzepatide, which is sold under the brand name Mounjaro for diabetes ...

(Reuters) -Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide ... that they have already ceased mass compounding.

Use of newer medications for weight loss and blood sugar management has surged between 2021 and 2023, especially tirzepatide ... to investigators from Mass General Brigham. These findings were ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...